Abstract
The use of immune checkpoint inhibitors in transplant recipients with malignancy is associated with the risk of graft failure due to acute rejection. There is limited literature regarding the use of Cemiplimab-rwlc (Libtayo) in kidney transplant patients. Here we present a case of using Cemiplimab-rwlc (Libtayo), a Programmed Death receptor-1 (PD-1) blocking antibody for locally advanced and metastatic Cutaneous Squamous Cell Carcinoma (CSCC), in a kidney transplant recipient.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
